NIDDK

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Retrieved on: 
화요일, 5월 21, 2024
Proton, Principal, Bangladesh Technical Education Board, Patient, Pharmacokinetics, MASH, Liver, Liver disease, University, Doctor of Philosophy, Therapy, Armed Forces Medical College, SAN, MBA, UCSD, MD, NIDDK, Magnetic resonance, NAFLD, Magnetic resonance imaging, Division, Digestive, Safety, Kidney, University of California, Hepatology, NIH

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Key Points: 
  • The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.
  • “Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • In addition, I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study.
  • “The excellent potency and PK profile makes ALG-055009 a compelling potential treatment option for MASH patients.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Retrieved on: 
월요일, 5월 6, 2024
Duke University Hospital, University, T1D, MACP, SAB, NIH, University of Miami, Psychology, Immunotherapy, Thomas Jefferson University, Research, Immunomodulation, NIDDK, Metabolism, Pediatrics, Pennsylvania State University, FRCP, Internal medicine, Division, Pharmaceutical industry

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

Key Points: 
  • MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.
  • “Dr.
  • Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J. Reich, SAB’s chairman and Chief Executive Officer.
  • “His deep expertise in type 1 diabetes research and leadership in the field will provide insights that will be invaluable to our SAB-142 program.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
월요일, 4월 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction

Retrieved on: 
화요일, 2월 13, 2024
ADAP, SAN, Real-time, Doctor of Philosophy, NPV, PPV, Laboratory developed test, Risk, Autoantibody, Carolyn Bertozzi, Risk assessment, CLIA, RBA, T1D, CAP, NIDDK, Public, Pharmaceutical industry

Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.

Key Points: 
  • Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.
  • This pivotal study underscores the ADAP assay's ability to detect islet autoantibodies, which are indicative of a high risk of progression to clinical T1D.
  • Dr. Jason Tsai, PhD, CTO of Enable Biosciences, elaborates on the significance of the findings: "These study results reinforce the strength of our ADAP technology in early T1D detection.
  • For more insights into Enable Biosciences and the impact of their ADAP technology, please visit www.enablebiosciences.com .

Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology

Retrieved on: 
화요일, 12월 19, 2023
Carolyn Bertozzi, Autoantibody, Risk, SBIR, Validation, FDA, Digestive, Disease, Kidney, SAN, Doctor of Philosophy, NIDDK, Type 1 diabetes, ADAP, Safety

A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.

Key Points: 
  • A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.
  • Dr. Jason Tsai, PhD, Chief Technical Officer at Enable Biosciences, shared his enthusiasm: "This Phase IIB SBIR award from NIDDK is a testament to our dedication to transforming T1D testing.
  • The NIDDK's support is pivotal for Enable Biosciences in its pursuit of FDA clearance for its innovative T1D test.
  • For more information about Enable Biosciences and their cutting-edge approach to T1D testing, visit www.enablebiosciences.com or contact their media team for further details and inquiries.

PREVISE FUELS GROWTH OF ITS BARRETT'S ESOPHAGUS RISK STRATIFICATION TEST WITH A COMPETITIVE $1.8M SBIR GRANT

Retrieved on: 
목요일, 10월 12, 2023
Physician, Biomarker, Johns Hopkins School of Medicine, Barrett's esophagus, Risk, Kidney, Methylation, Health, NIDDK, Cancer, Gastroenterology, Esophageal cancer, Bangladesh Technical Education Board, Digestive, National Institute of Diabetes and Digestive and Kidney Diseases, Patient, NIH, Small Business Innovation Research, SBIR, Pharmaceutical industry

BALTIMORE, Oct. 12, 2023 /PRNewswire/ -- Previse, maker of Esopredict, a clinically available test that analyzes methylation of biomarkers to assess the risk of esophageal cancer developing in patients with Barrett's esophagus and currently provides GI physicians with results within one week, was awarded a prestigious and highly competitive $1.8M Direct to Phase II SBIR (Small Business Innovation Research) grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

Key Points: 
  • Esopredict™, Previse's Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett's Esophagus Prognostic Test.
  • Securing the SBIR grant for this project involved Previse collaborating with investigators at Johns Hopkins University School of Medicine to submit intensive research and commercialization plans to the NIH, outlining the path Previse is taking to accelerate the adoption of the Esopredict test.
  • Esopredict is a game-changing assay rooted in highly accurate methylation-based analysis, which empowers gastroenterologists to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus.
  • Previse CEO Daniel Lunz said: "This substantial grant awarded by the NIH underlines the potential impact of Previse's Esopredict assay and methylation technology.

National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease

Retrieved on: 
월요일, 9월 25, 2023
Transfer, NIDDK, Stenosis, Antigen, Diarrhea, STTR, Weight loss, Cancer, National Institute of Diabetes and Digestive and Kidney Diseases, Research, Abdominal pain, Steroid, Deoxycytidine kinase, Kidney, Patient, Colorectal cancer, Immune system, Cell division, CD4, Lymphocyte, Digestive, Plasma protein binding, NIH, Foundation for the National Institutes of Health, Safety, Fatigue, Disease, Pharmaceutical industry, Vaccine

The award provides $400,000 to translate proof-of-principle early research findings of Trethera’s clinical stage first-in-class drug, TRE-515, as an oral therapy for Crohn’s disease.

Key Points: 
  • The award provides $400,000 to translate proof-of-principle early research findings of Trethera’s clinical stage first-in-class drug, TRE-515, as an oral therapy for Crohn’s disease.
  • Crohn’s disease is a chronic, relapsing, inflammatory gastrointestinal disorder that can present with diarrhea, fatigue, severe abdominal pain, and weight loss.
  • Almost 1 million Americans suffer from the disease today, with complications including intestinal fistulas, strictures, and colorectal cancer.
  • The disease is primarily driven by autoreactive CD4 T cells of the patient’s own immune system that target antigens in the gut.

National Institutes of Health To Locate Signature Research Program on the Phoenix Bioscience Core

Retrieved on: 
금요일, 9월 15, 2023
Knowledge, NIDDK, Translational Genomics Research Institute, Partnership, Obesity, University, Epidemiology, Cushman, PBC, SmithGroup, Knowledge enterprise, Innovation, Research, Genomics, CBRE, Bangladesh Technical Education Board, Marketing Executives Network Group, Entrepreneurship, GateWay Community College, Risk, Arizona State University, Engineering, School, Medical school, Growth, ASU, United, Biomedical sciences, Digestive, Health, NIH, World Health Organization, Pharmaceutical industry, Management, City, Wawatay Native Communications Society

PHOENIX, Sept. 15, 2023 /PRNewswire/ -- Wexford Science & Technology, LLC today announced that the National Institutes of Health has signed a lease at 850 PBC and will use the space to accommodate the Phoenix Epidemiology & Clinical Research Branch of the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).  This innovative basic, translational, and clinical research center will occupy the entire 7th floor of 850 PBC, comprising approximately 35,000 square feet.

Key Points: 
  • "We are thrilled to announce the expansion of National Institutes of Health - NIDDK on the Phoenix Bioscience Core at 850 PBC," said Kyle Jardine, Market Executive at Wexford Science & Technology.
  • "NIH is a key research catalyst for our existing tenants, and reaffirms the PBC as Arizona's central hub for life science research and entrepreneurship.
  • The new lease at 850 PBC will allow all sections of NIDDK Phoenix to be co-located in the Phoenix Bioscience Core.
  • "It's an incredible win for Phoenix that more members of the NIDDK team will join our Phoenix Bioscience Core," City of Phoenix Mayor Kate Gallego said.

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023

Retrieved on: 
월요일, 9월 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NIDDK, Pancreatic cancer, Human, Drug development, NOD, Bio, SBIR, Bone marrow, NHL, National Institutes of Health, Clinical trial, Cancer, Multimedia, Research, Natural killer T cell, National Cancer Institute, Type 1, AVM, Patient, Adoptive cell transfer, Animal, Growth, FDA, NCI, Service, Safety, Pharmaceutical industry, Vaccine, TCR

With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.

Key Points: 
  • With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.
  • (Graphic: Business Wire)
    In June 2023, AVM Biotechnology was selected as a 2023-2024 National Cancer Institute (NCI) Showcase Company for their Small Business Innovation Research (SBIR) Investor Initiatives.
  • AVM Biotechnology has previously been awarded five (5) highly competitive National Institute of Health SBIR grants; three (3) of these from the National Cancer Institute.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

NDRI Receives $3.7 Million Grant from NIH to Continue the Development of NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program

Retrieved on: 
수요일, 9월 6, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Hospitals, Genetics, NIDDK, Tissue, National Disease Research Interchange, Division of Program Coordination, Planning, and Strategic Initiatives, National Institute of Allergy and Infectious Diseases, Partnership, Arthritis, NEI, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Skin condition, Lung, Bangladesh Technical Education Board, MS, NHLBI, Kidney, NIAMS, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases, NDRI, Human musculoskeletal system, NIAID, Digestive, NIH, Infection, Pharmaceutical industry, Management

This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.

Key Points: 
  • This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.
  • The HTORR Program supports investigators across the full spectrum of research with access to normal and diseased human biospecimens.
  • “NDRI is grateful to the NIH for the support of our expanding HTORR program,” said Bill Leinweber, President and CEO of NDRI.
  • This grant renewal includes multiple enhancements such as a new Pilot Program, Pathology Service Options, and a Pathology Consultant Committee.